NYSEAMERICAN:PTHS

Pelthos Therapeutics (PTHS) Stock Price, News & Analysis

Pelthos Therapeutics logo
$6.84 0.00 (0.00%)
As of 11/17/2026 04:10 PM Eastern

About Pelthos Therapeutics Stock (NYSEAMERICAN:PTHS)

Advanced

Key Stats

Today's Range
$6.76
▼
$7.15
50-Day Range
$6.84
▼
$23.52
52-Week Range
$6.76
▼
$32.51
Volume
74,257 shs
Average Volume
67,709 shs
Market Capitalization
$26.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.33
Consensus Rating
Moderate Buy

Company Overview

Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. Its portfolio includes ZELSUVMI (berdazimer) topical gel, an FDA-approved prescription treatment for molluscum contagiosum, a viral skin infection.

ZELSUVMI is approved in the United States for adults and children aged one year and older. The topical treatment is designed for application at home, providing an option for patients and caregivers managing the condition.

The company’s known commercial focus is the U.S. dermatology market. Publicly available information about its broader product pipeline and international operations is limited.

AI Generated. May Contain Errors.

Pelthos Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

PTHS MarketRank™: 
3.10209249633 of 5 stars

Pelthos Therapeutics scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pelthos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Pelthos Therapeutics has a consensus price target of $48.33, representing about 606.6% upside from its current price of $6.84.

  • Amount of Analyst Coverage

    Pelthos Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Pelthos Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Pelthos Therapeutics are expected to grow in the coming year, from ($14.49) to ($4.76) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pelthos Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pelthos Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    4.95% of the float of Pelthos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pelthos Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pelthos Therapeutics has recently increased by 11.40%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pelthos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pelthos Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Pelthos Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Pelthos Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Pelthos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,434.00 in company stock.

  • Percentage Held by Insiders

    16.40% of the stock of Pelthos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    77.96% of the stock of Pelthos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pelthos Therapeutics' insider trading history.
Receive PTHS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pelthos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTHS Stock News Headlines

This Could Be the Biggest Monetary Shift in 50 Years
The U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.tc pixel
Pelthos Therapeutics Q3 Earnings Call Highlights
See More Headlines

PTHS Stock Analysis - Frequently Asked Questions

Pelthos Therapeutics' stock was trading at $25.94 at the beginning of the year. Since then, PTHS stock has decreased by 73.6% and is now trading at $6.84.

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) issued its earnings results on Thursday, November, 12th. The company reported ($2.04) earnings per share for the quarter, beating analysts' consensus estimates of ($2.83) by $0.79. The firm earned $15.40 million during the quarter. Pelthos Therapeutics had a negative net margin of 123.24% and a negative trailing twelve-month return on equity of 432.23%.
Read the conference call transcript
.

Top institutional investors of Pelthos Therapeutics include AIGH Capital Management LLC (6.68%) and State Street Corp (0.28%). Insiders that own company stock include Ezra M Friedberg and Richard Malamut.
View institutional ownership trends
.

Shares of PTHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSEAMERICAN:PTHS
CIK
1919246
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

High Price Target
$64.00
Low Price Target
$21.00
Potential Upside/Downside
+606.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.32 million
Net Margins
-123.24%
Pretax Margin
-165.66%
Return on Equity
-432.23%
Return on Assets
-40.24%

Debt

Debt-to-Equity Ratio
3.40
Current Ratio
1.78
Quick Ratio
1.10

Sales & Book Value

Annual Sales
$16.80 million
Price / Sales
1.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.57) per share
Price / Book
-4.36

Miscellaneous

Outstanding Shares
3,930,000
Free Float
3,286,000
Market Cap
$26.88 million
Optionable
N/A
Beta
3.41
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NYSEAMERICAN:PTHS) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners